Tumor endothelial marker 8 promotes cancer progression and metastasis
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Tumor endothelial marker 8 promotes cancer progression and metastasis. / Høye, Anette M.; Tolstrup, Sofie D.; Horton, Edward R.; Nicolau, Monica; Frost, Helen; Woo, Jung H.; Mauldin, Jeremy P.; Frankel, Arthur E.; Cox, Thomas R.; Erler, Janine T.
In: OncoTarget, Vol. 9, No. 53, 2018, p. 30173-30188.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Tumor endothelial marker 8 promotes cancer progression and metastasis
AU - Høye, Anette M.
AU - Tolstrup, Sofie D.
AU - Horton, Edward R.
AU - Nicolau, Monica
AU - Frost, Helen
AU - Woo, Jung H.
AU - Mauldin, Jeremy P.
AU - Frankel, Arthur E.
AU - Cox, Thomas R.
AU - Erler, Janine T.
PY - 2018
Y1 - 2018
N2 - Every year more than 8 million people suffer from cancer-related deaths worldwide [1]. Metastasis, the spread of cancer to distant sites, accounts for 90% of these deaths. A promising target for blocking tumor progression, without causing severe side effects [2], is Tumor Endothelial Marker 8 (TEM8), an integrin-like cell surface protein expressed predominantly in the tumor endothelium and in cancer cells [3, 4]. Here, we have investigated the role of TEM8 in cancer progression, angiogenesis and metastasis in invasive breast cancer, and validated the main findings and important results in colorectal cancer. We show that the loss of TEM8 in cancer cells results in inhibition of cancer progression, reduction in tumor angiogenesis and reduced metastatic burden in breast cancer mouse models. Furthermore, we show that TEM8 regulates cancer progression by affecting the expression levels of cell cycle-related genes. Taken together, our findings may have broad clinical and therapeutic potential for breast and colorectal primary tumor and metastasis treatment by targeting TEM8.
AB - Every year more than 8 million people suffer from cancer-related deaths worldwide [1]. Metastasis, the spread of cancer to distant sites, accounts for 90% of these deaths. A promising target for blocking tumor progression, without causing severe side effects [2], is Tumor Endothelial Marker 8 (TEM8), an integrin-like cell surface protein expressed predominantly in the tumor endothelium and in cancer cells [3, 4]. Here, we have investigated the role of TEM8 in cancer progression, angiogenesis and metastasis in invasive breast cancer, and validated the main findings and important results in colorectal cancer. We show that the loss of TEM8 in cancer cells results in inhibition of cancer progression, reduction in tumor angiogenesis and reduced metastatic burden in breast cancer mouse models. Furthermore, we show that TEM8 regulates cancer progression by affecting the expression levels of cell cycle-related genes. Taken together, our findings may have broad clinical and therapeutic potential for breast and colorectal primary tumor and metastasis treatment by targeting TEM8.
KW - Angiogenesis
KW - Cancer
KW - Metastasis
KW - Tumor endothelial marker 8
U2 - 10.18632/oncotarget.25734
DO - 10.18632/oncotarget.25734
M3 - Journal article
C2 - 30046396
AN - SCOPUS:85049739088
VL - 9
SP - 30173
EP - 30188
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 53
ER -
ID: 211864079